Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegeneration and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for UCHL1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | UCHL1 Wild Type & C90S Mutant Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or HEK293 expressed. |
View UCHL1 Products |
| Gene Delivery | UCHL1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression studies. |
View UCHL1 Products |
| Benchmark Ab | Anti-UCHL1 Recombinant Antibody Recombinant positive control for ELISA, Western Blot, and IHC. |
View UCHL1 Products |
| Validator | UCHL1 siRNA Set For target knockdown verification in cellular assays. |
View UCHL1 Products |
| Related Target A | USP7 Counter-screening target to evaluate deubiquitinating enzyme (DUB) selectivity. |
View USP7 Products |
| Related Target B | Ubiquitin Essential modifier substrate for deubiquitinating activity assays. |
View Ubiquitin Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| DUB Subfamily Off-target Screening | Active wild-type and inactive mutant (C90S) proteins strictly verified by mass spectrometry and SDS-PAGE purity (>95%). |
| Diagnostic Assay Calibration (TBI/Stroke) | HEK293 expressed recombinant UCHL1 preserving native post-translational modifications, with controlled endotoxin levels. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available for reference curves. |
| False Positives in Small Molecule Screens | Validated siRNA sets included to confirm target-specific biological knockdown. |
Live UCHL1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for UCHL1 therapeutics is intensifying, with major players shifting focus from traditional diagnostics to small molecule inhibitors and PROTACs. As first-generation therapies targeting the ubiquitin-proteasome system (UPS) reach the clinic, the next wave of R&D is targeting selective deubiquitinating enzymes (DUBs) to address oncology and neurodegenerative disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Mission Therapeutics, Almac Discovery | Oncology (SCLC, Breast Cancer), Fibrosis | Selectivity Assay (Need Mutant vs WT Proteins and USP7 counter-screening panel) |
| PROTACs / Degraders | Arvinas, Ubiquigent | Neurodegenerative Diseases, Oncology | Ubiquitination Kinetics (Need high-purity Ubiquitin and UCHL1 proteins) |
| Diagnostics / Biomarkers | Abbott Diagnostics, Bio-Rad | Traumatic Brain Injury (TBI), Stroke | High-Affinity Validation (Need sequence-verified antigens and benchmark antibodies) |